Mar 17, 2016 - manufacturing and marketing. March 25, 2013. Date of initial marketing in Japan. June 27, 2013. Manufactu
Hisamitsu Pharmaceutical Co., Inc. Asahi Kasei Pharma Corp. March 17, 2016
Discontinuation of joint sales of NEOXY® Tape 73.5 mg transdermal overactive bladder treatment medication Hisamitsu Pharmaceutical Co., Inc., (Head office: Tosu city, Saga Prefecture, Japan; President & CEO: Hirotaka Nakatomi; hereinafter referred to as Hisamitsu) and Asahi Kasei Pharma Corp. (Head office: Chiyoda-ku, Tokyo, Japan; President: Kazuyoshi Hori; hereinafter referred to as Asahi Kasei) reached agreement to discontinue their joint sales of NEOXY® Tape 73.5 mg, a transdermal overactive bladder treatment medication, on June 26, 2016. While Hisamitsu and Asahi Kasei have jointly sold NEOXY® Tape 73.5 mg since June 2013, the agreement to discontinue joint sales was reached as a result of discussion between the two companies. Asahi Kasei will discontinue sales within three months from June 26, 2016, when its inventory of NEOXY® Tape 73.5 mg is depleted. After that, Hisamitsu will sell NEOXY® Tape 73.5 mg alone. Reference: Trade name Active pharmaceutical ingredient Indication Dose and Administration
Packaging NHI drug price Date of approval for manufacturing and marketing Date of initial marketing in Japan Manufactured and distributed by
NEOXY® Tape 73.5 mg Oxybutynin hydrochloride Urinary urgency, frequent urination, and urge urinary incontinence caused by overactive bladders Usually apply one sheet (73.5 mg of oxybutynin hydrochloride) once a day on the lower abdomen, lower back, or thigh of an adult and replace every 24 hours. 70 sheets (1 sheet/pack × 70), 280 sheets (1 sheet/pack × 280) 194.80 yen/sheet March 25, 2013 June 27, 2013 Hisamitsu Pharmaceutical Co., Inc.
Page 1 of 1
